tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Zhang YJ et al. | [Hypertrophy of the heart: calcineurin-NFAT pathway may be a new therapeutic target]. | 2006 | Yao Xue Xue Bao | pmid:17184105 |
| Wang M et al. | Studies on the effects of the immunosuppressant FK-506 on the high-risk corneal graft rejection. | 2002 | Yan Ke Xue Bao | pmid:15510746 |
| Li S et al. | Experiment study of retinal ultrastructure after intravitreal FK506. | 2004 | Yan Ke Xue Bao | pmid:15124532 |
| Xie H et al. | Effect of topical FK506 used alone or combined with keratoplasty on patients with recurrent Mooren's corneal ulcer. | 2006 | Yan Ke Xue Bao | pmid:17378150 |
| Ma H et al. | [The effect of FK506 on the proliferation of HRCECs]. | 2006 | Yan Ke Xue Bao | pmid:17378157 |
| Kagaya H et al. | Quantification and 24-hour monitoring of mycophenolic acid by high-performance liquid chromatography in Japanese renal transplant recipients. | 2006 | Yakugaku Zasshi | pmid:17139160 |
| Tayama Y et al. | [Influence of tacrolimus and ciprofloxacin on glucose metabolism]. | 2007 | Yakugaku Zasshi | pmid:17978565 |
| Naito T | [Optimal immunosuppressive therapy based on pharmacokinetics and pharmacodynamics of antimetabolites in clinical practice]. | 2010 | Yakugaku Zasshi | pmid:21139397 |
| Yamaguchi K et al. | [Case of encephalopathy seemingly caused by tacrolimus at blood concentration near the upper limit of therapeutic range]. | 2012 | Yakugaku Zasshi | pmid:22790031 |
| Nagao K et al. | [Drug development from natural fermentation products: establishing a manufacturing process which maximizes the potential of microorganisms]. | 2010 | Yakugaku Zasshi | pmid:21048405 |
| Fukudo M | [Individualized dosage regimen of immunosuppressive drugs based on pharmacokinetic and pharmacodynamic analysis]. | 2007 | Yakugaku Zasshi | pmid:17603267 |
| Sood S and Muthuraman A | Activity of tacrolimus: an immunosuppressant, in pyloric ligation-induced peptic ulcer in the rat. | 2009 | Yakugaku Zasshi | pmid:19952532 |
| Tanaka H et al. | [Discovery and development of a novel immunosuppressant, tacrolimus hydrate]. | 1997 | Yakugaku Zasshi | pmid:9306728 |
| Muraki Y | [Factors affecting the pharmacokinetics after living donor liver transplant]. | 2012 | Yakugaku Zasshi | pmid:23023417 |
| Iwamoto T et al. | [Successful treatment by tacrolimus in two patients with Osserman's grade III intractable myasthenia gravis and elderly IIb]. | 2004 | Yakugaku Zasshi | pmid:15067188 |
| Uchida K et al. | Pharmacokinetics of orally administered tacrolimus in lupus nephritis patients. | 2010 | Yakugaku Zasshi | pmid:20046074 |
| Niwa T et al. | Effect of cyclosporine and tacrolimus on cytochrome p450 activities in human liver microsomes. | 2007 | Yakugaku Zasshi | pmid:17202802 |
| Shimizu K | Development of New Liposome Targeting Strategies for Application of Disease Therapies. | 2017 | Yakugaku Zasshi | pmid:28049894 |
| Tanaka Y et al. | [Effect of tacrolimus on the pharmacokinetics and glucuronidation of SN-38, an active metabolite of irinotecan]. | 2013 | Yakugaku Zasshi | pmid:23328499 |
| Li J et al. | [Regulatory effect of FK506 on the expression of CD152 and PD-1 in the liver allo-recipients]. | 2008 | Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi | pmid:18177621 |